ScreenerHero

BEAMBeam Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · beamtx.com
29.76USD+2.37%Mkt Cap: 3.07B $P/E: —

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.07B $
Enterprise Value1.93B $
Revenue (TTM)156.04M $
Gross Profit-252.63M $
Net Income (TTM)-79.99M $
Revenue/Share1.511 USD
Last Price29.76 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees540
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.99
PEG—
EV/EBITDA-5.43
EV/Revenue12.38
P/S18.79
P/B2.66
EPS (TTM)-0.67
EPS (Forward)-4.74
52W Range
15.6062% of range38.26
52W High38.26 USD
52W Low15.60 USD
Profitability
Gross Margin-161.91%
Oper. Margin-25827.14%
EBITDA Margin-228.01%
Profit Margin-57.24%
ROE-6.46%
ROA-5.40%
Growth
Revenue Growth-94.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-345.10M $
CapEx (TTM)14.95M $
FCF Margin-154.99%
FCF Yield-7.87%
Net Debt-905.57M $
Net Debt/EBITDA2.55
Balance Sheet
Debt/Equity0.12
Current Ratio14.57
Quick Ratio14.25
Book Value/Sh10.69 USD
Cash/Share11.54 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)52.15 USD
Upside (mean)+75.2%
Target Range26.00 USD – 80.00 USD
$26.00+75.2% to mean$80.00
# Analysts13
Ownership
Shares Out.103.29M
Float88.24M
Insiders1.37%
Institutions107.88%
Short Interest
Short Ratio10.1d
Short % Float35.17%
Short % Out.22.75%
Shares Short23.50M
Short (prev mo.)22.88M
Technical
SMA 5029.90 (-0.5%)
SMA 20028.13 (+5.8%)
Beta2.21
S&P 52W Chg18.16%
Avg Vol (30d)1.93M
Avg Vol (10d)1.69M
Technical Indicators
RSI (14)58.5
MACD-0.3357
MACD Signal-0.8191
MACD Hist.+0.4834
BB Upper29.23 USD
BB Middle26.82 USD
BB Lower24.42 USD
BB Width17.95%
ATR (14)1.573 USD
Vol Ratio (20d)1.46x